![The cost of electrifying all households in 40 Sub-Saharan African countries by 2030 | Nature Communications The cost of electrifying all households in 40 Sub-Saharan African countries by 2030 | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-023-40612-3/MediaObjects/41467_2023_40612_Fig1_HTML.png)
The cost of electrifying all households in 40 Sub-Saharan African countries by 2030 | Nature Communications
![Frontiers | Carbamazepine Increases the Risk of Sudden Cardiac Arrest by a Reduction of the Cardiac Sodium Current Frontiers | Carbamazepine Increases the Risk of Sudden Cardiac Arrest by a Reduction of the Cardiac Sodium Current](https://www.frontiersin.org/files/Articles/891996/fcell-10-891996-HTML/image_m/fcell-10-891996-g001.jpg)
Frontiers | Carbamazepine Increases the Risk of Sudden Cardiac Arrest by a Reduction of the Cardiac Sodium Current
![Concept Embedding Models: Beyond the Accuracy-Explainability Trade-Off | by Pietro Barbiero | Towards Data Science Concept Embedding Models: Beyond the Accuracy-Explainability Trade-Off | by Pietro Barbiero | Towards Data Science](https://miro.medium.com/v2/resize:fit:400/1*z6reZErt48xa0D5r1D0-Ww.png)
Concept Embedding Models: Beyond the Accuracy-Explainability Trade-Off | by Pietro Barbiero | Towards Data Science
![Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial - The Lancet Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial - The Lancet](https://www.thelancet.com/cms/asset/104b731b-8c0c-4b61-b1b3-6883105d8a1c/gr2.jpg)
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial - The Lancet
![PDF) Development of in situ melanoma after allogeneic bone marrow transplantation in Griscelli syndrome type II PDF) Development of in situ melanoma after allogeneic bone marrow transplantation in Griscelli syndrome type II](https://i1.rgstatic.net/publication/5933686_Development_of_in_situ_melanoma_after_allogeneic_bone_marrow_transplantation_in_Griscelli_syndrome_type_II/links/5bffec71a6fdcc1b8d4a7602/largepreview.png)
PDF) Development of in situ melanoma after allogeneic bone marrow transplantation in Griscelli syndrome type II
![Frontiers | Prefusion-specific antibody-derived peptides trivalently presented on DNA-nanoscaffolds as an innovative strategy against RSV entry Frontiers | Prefusion-specific antibody-derived peptides trivalently presented on DNA-nanoscaffolds as an innovative strategy against RSV entry](https://www.frontiersin.org/files/Articles/994843/fviro-02-994843-HTML-r1/image_m/fviro-02-994843-g001.jpg)
Frontiers | Prefusion-specific antibody-derived peptides trivalently presented on DNA-nanoscaffolds as an innovative strategy against RSV entry
![Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries - The Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries - The](https://www.thelancet.com/cms/asset/d0465322-810a-41c8-bda6-d05d18d3f418/gr1.jpg)